<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989636</url>
  </required_header>
  <id_info>
    <org_study_id>J16138</org_study_id>
    <secondary_id>IRB00117650</secondary_id>
    <secondary_id>NCI-2016-01638</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>18-020</secondary_id>
    <secondary_id>CA209-594</secondary_id>
    <nct_id>NCT02989636</nct_id>
  </id_info>
  <brief_title>Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma</brief_title>
  <official_title>Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chordoma Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects of nivolumab with or without stereotactic&#xD;
      radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where&#xD;
      it started to other places in the body. Monoclonal antibodies, such as nivolumab, may&#xD;
      interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a&#xD;
      specialized radiation therapy that delivers a single, high dose of radiation directly to the&#xD;
      tumor and may cause less damage to normal tissue. It is not yet known whether giving&#xD;
      nivolumab with or without stereotactic radiosurgery may work better in treating patients with&#xD;
      chordoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety profile of nivolumab alone and nivolumab in combination with&#xD;
      stereotactic radiosurgery to treat patients with recurrent or advanced chordoma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate toxicity and tolerability of nivolumab alone and nivolumab in combination with&#xD;
      stereotactic radiosurgery.&#xD;
&#xD;
      II. To estimate growth modulation index on target lesion. III. To estimate a clinical&#xD;
      response (partial response [PR] + complete response [CR] within 6 month + stable disease [SD]&#xD;
      beyond 6 months).&#xD;
&#xD;
      IV. To assess progression-free survival and progression-free survival (PFS) rate at 6 months.&#xD;
&#xD;
      V. To assess overall survival rate at 1 year, 3 years and 5 years.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To explore peripheral blood immune response during and after treatment.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat&#xD;
      every 14 days for 2 years in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery&#xD;
      (SRS) as per standard of care on day 8 of course 1.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 100 days and every 10 weeks&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Up to 12 weeks after initial dose of nivolumab</time_frame>
    <description>Proportion of serious adverse events will be estimated using the binomial distribution along with 95% confidence interval (exact method).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Chordoma</condition>
  <arm_group>
    <arm_group_label>Arm I (nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (nivolumab, SRS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (nivolumab)</arm_group_label>
    <arm_group_label>Arm II (nivolumab, SRS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (nivolumab)</arm_group_label>
    <arm_group_label>Arm II (nivolumab, SRS)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Undergo SRS</description>
    <arm_group_label>Arm II (nivolumab, SRS)</arm_group_label>
    <other_name>Stereotactic External Beam Irradiation</other_name>
    <other_name>stereotactic external-beam radiation therapy</other_name>
    <other_name>Stereotactic Radiation Therapy</other_name>
    <other_name>Stereotactic Radiotherapy</other_name>
    <other_name>stereotaxic radiation therapy</other_name>
    <other_name>stereotaxic radiosurgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed diagnosis of chordoma; the pathologic&#xD;
             confirmation may be from another metastatic site&#xD;
&#xD;
          -  Patients may have metastases, with newly identified peripheral metastases&#xD;
&#xD;
          -  Cross-sectional imaging evidence of progression of recurrent or metastatic disease&#xD;
&#xD;
          -  Previous treatment information (name of agent, treatment starting date, and date of&#xD;
             progression) must be available for review&#xD;
&#xD;
          -  Measurable disease in one or more site. (Per RECIST criteria: Measurable lesions are&#xD;
             defined as those that can be accurately measured in at least one dimension (longest&#xD;
             diameter to be recorded) as &gt;= 10 mm with CT scan, MRI, or calipers by clinical exam.&#xD;
             All tumor measurements must be recorded in millimeters (or decimal fractions of&#xD;
             centimeters)).&#xD;
&#xD;
          -  Karnofsky performance scale &gt;= 70%&#xD;
&#xD;
          -  White blood cells (WBC) &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 x institutional upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =&lt;&#xD;
             2.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine within normal institutional limits OR according to Johns Hopkins magnetic&#xD;
             resonance imaging (MRI) policy&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) should use an adequate method to avoid&#xD;
             pregnancy for 5 months plus the time required for nivolumab to undergo approximately&#xD;
             five half-lives) after the last dose of investigational drug; in order for a woman to&#xD;
             be determined not of child-bearing potential, she must have &gt;= 12 months of&#xD;
             non-therapy induced amenorrhea or be surgically sterile&#xD;
&#xD;
          -  Men receiving nivolumab and who are sexually active with WOCBP will be instructed to&#xD;
             adhere to contraception for a period of 7 months after the last dose of&#xD;
             investigational product&#xD;
&#xD;
          -  Ability to understand and the willingness to sign written informed consent document(s)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy within 21 days or 5 half-lives (whichever is shorter) days of&#xD;
             starting treatment&#xD;
&#xD;
          -  Prior therapy with investigational drugs within 21 days or at least 5 half-lives&#xD;
             (whichever is shorter) before study administration&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL-2 antibody&#xD;
&#xD;
          -  Neurologic dysfunction that would confound the evaluation of neurologic and other&#xD;
             adverse events&#xD;
&#xD;
          -  Known allergy to compounds of similar chemical or biologic composition to nivolumab&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Known history of human immunodeficiency virus&#xD;
&#xD;
          -  Active infection requiring therapy, including positive tests for hepatitis B surface&#xD;
             antigen or hepatitis C ribonucleic acid (RNA)&#xD;
&#xD;
          -  Active autoimmune disease, history of autoimmune disease or history of syndrome that&#xD;
             required systemic steroids or immunosuppressive medications, e.g. organ, tissue, or&#xD;
             allogenic hematopoietic stem cell transplant (HSCT) recipients. Exceptions include&#xD;
             those with resolved childhood asthma/atopy. Subjects with asthma who require&#xD;
             intermittent use of bronchodilators (such as albuterol) will not be excluded from this&#xD;
             study. Subjects are also permitted to enroll if they have vitiligo, type I diabetes&#xD;
             mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone&#xD;
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to&#xD;
             recur in the absence of an external trigger&#xD;
&#xD;
          -  Patients should be excluded if they have a condition requiring systemic treatment with&#xD;
             either corticosteroids (&gt; 10 mg daily prednisone equivalents) or other&#xD;
             immunosuppressive medications within 14 days of study drug administration; inhaled or&#xD;
             topical steroids and adrenal replacement doses &gt; 10 mg daily prednisone equivalents&#xD;
             are permitted in the absence of active autoimmune disease&#xD;
&#xD;
          -  Use of any vaccines against infectious diseases (e.g. varicella, influenza, etc.) up&#xD;
             to 4 weeks (28 days) before receiving nivolumab&#xD;
&#xD;
          -  Prisoners or subjects who are compulsorily detained for treatment of either a&#xD;
             psychiatric or physical (e.g. infectious disease) illness&#xD;
&#xD;
          -  Prior radiation doses equivalent to, or greater than, 8000 cGy in 200 cGy fractions&#xD;
&#xD;
          -  Any radiation to the target lesions within 6 months of enrollment&#xD;
&#xD;
          -  Unable to meet radiation treatment plan parameters&#xD;
&#xD;
          -  Unavailable for follow up visits after treatment&#xD;
&#xD;
          -  Prior malignancy unless disease free for ≥ 2 years. Curatively treated basal or&#xD;
             squamous cell carcinoma of the skin, totally excised melanoma of stage IIA or lower,&#xD;
             low- or intermediate-grade localized prostate cancer (Gleason sum ≤7), and&#xD;
             curatively-treated carcinoma in situ of the cervix, breast, or bladder are allowed&#xD;
             regardless.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Kleinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Wollett</last_name>
    <phone>4105027752</phone>
    <email>jwollet1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly K. Szajna, RN, BSN</last_name>
      <phone>410-502-4081</phone>
      <email>kszajna1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Whitney Webb, RN, MSN</last_name>
      <phone>4109557008</phone>
      <email>wwebb10@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Kleinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Lim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Meyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mehallow</last_name>
      <phone>212-639-2739</phone>
      <email>mehallom@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Emily Gelb</last_name>
      <phone>646-888-4592</phone>
      <email>gelbe@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Yoshiya (Josh) Yamada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 8, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

